Under RIDDOR (a health and safety regulation) employers now have a duty to report cases where employees have contracted COVID as a result of direct exposure due to work activities. Three specific circumstances have been identified: 1) “An accident or incident at work has, or could have, led to the release or escape of coronavirus”, 2) “A worker has been diagnosed with COVID-19 attributed to an occupational exposure to coronavirus.” 3) A worker dies as a result of occupational exposure to coronavirus.
News
Prof Dell’ Accio and Dr Suzanne Eldridge from Queen Mary University of London have discovered a new therapeutic treatment for osteochondral defects shown to regenerate the cartilage and provide rapid, long-term pain relief.
These findings have been published in Science of Translational Medicine https://stm.sciencemag.org/content/12/559/eaax9086 and featured widely in the media https://sciencetm.altmetric.com/details/89347825#score.
New report shows 10% of UK’s top female BioBusiness talent is based at Stevenage Bioscience Catalyst
A report released today by BioBeat showcasing the 30 top female leaders in the UK bioscience sector has named three people from organisations based at Stevenage Bioscience Catalyst (SBC), totalling 10% of the list.
The three mentioned leaders based at SBC are Shree Patel from Achilles Therapeutics, Nicole Mathon from LifeArc and Bakul Gupta from ImmTune Therapies.
Leading pharmaceutical and biotech product development consultancy Boyds has added to its regulatory team with the appointment of experienced toxicologist, Dr Geoffrey Rose in response to the continued increase in demand for its dedicated regulatory services.
With more than 20 years’ regulatory experience across the full clinical product lifecycle, regulatory toxicologist Geoffrey joins Boyds as Director of Regulatory Affairs.
New Funds to Drive Further Commercialisation of Rare and Inherited Cancer Applications and Expansion into Oncology, Wellness and Pharma Collaborations
Cambridge, United Kingdom – 9 November 2020 - Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, is pleased to announce the completion of its Series C funding round, raising US$50m/£39m.
Biocair, a global logistics company dedicated to the life sciences, has partnered with Roylance Pharma to deliver fully integrated transportation and storage services for temperature-controlled pharmaceutical and biological materials.
- Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability
- PhoreMost’s SITESEEKER® platform will identify active peptides to be deployed within Oxford Biomedica’s LentiVector ® delivery system
- Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431
- Inhibitors discovered at Domainex via virtual and fragment screening
Vienna, Austria and Saffron Waldon, UK, 9th November 2020 / Sciad Newswire / APEIRON Biologics AG, a privately-held biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex Ltd to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery.
Appleyard Lees IP LLP has recently announced it has been recognised by three top legal industry analysts in the past month.
Eminent legal publishers Chambers & Partners 2021 has named Appleyard Lees a leading intellectual property firm for another consecutive year. Also, several Appleyard Lees attorneys are listed in IP Stars 2021, while The Legal 500 2021 has named Appleyard Lees a leading law firm for its patent and trade mark prosecution work.
In all three programmes, client feedback plays a large part in the research undertaken to rate a firm or attorney.